Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018

AUTHORS

Ilseung Choi , Naokuni Uike

ABSTRACT

Ibritumomab tiuxetan labeled with yttrium-90 (90Y) is one of the excellent therapeutic options for patients with low-grade B cell non-Hodgkin lymphoma (NHL) who have relapsed disease after first-line chemotherapy regimens and are reluctant to the precedent therapy. The overall response rate (ORR) of 80–90% and the complete response rate (CR) of 30–69% have been reported for patients with relapsed or refractory low-grade B cell NHL. It has also an established role as a consolidation therapy agent after first-line chemotherapy. Ibritumomab tiuxetan has also proved to be an efficient and feasible treatment option as first-line therapy. The short-term toxicity associated with ibritumomab tiuxetan is mainly reversible bone marrow suppression. For diffuse large B cell lymphoma, which is the most frequent NHL subtype, ibritumomab tiuxetan has been also introduced as conditioning therapy added to conventional conditioning regimens before stem cell transplantation. More... »

PAGES

1-8

Book

TITLE

Resistance to Ibritumomab in Lymphoma

ISBN

978-3-319-78237-9
978-3-319-78238-6

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_1

DOI

http://dx.doi.org/10.1007/978-3-319-78238-6_1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1103656348


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Hospital Organization Kyushu Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.470350.5", 
          "name": [
            "National Kyushu Cancer Center", 
            "National Hospital Organization Kyushu Cancer Center"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choi", 
        "givenName": "Ilseung", 
        "id": "sg:person.0745256126.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745256126.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Saga-Ken Medical Centre Koseikan", 
          "id": "https://www.grid.ac/institutes/grid.416533.6", 
          "name": [
            "Saga-ken Medical Centre Koseikan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uike", 
        "givenName": "Naokuni", 
        "id": "sg:person.01002213667.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002213667.77"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2008.00999.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001118083"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clml.2011.03.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010638416"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012922266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0529", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018226479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019581117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.41.1553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019738515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2005-01-0016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019752393"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.50.3110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021633071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.2882", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022216179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.17.2015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022228089"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428194.2011.635857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022329553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2016.07.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022344315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2005.00120.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023063407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1349-7006.2005.00120.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023063407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-01-068056", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025973696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2013.093450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026609111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.6400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027703974"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-08-3175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033024465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2003.10.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034380348"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2003.10.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034380348"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.6531", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035060800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22066", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036856009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-014-1636-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039937702", 
          "https://doi.org/10.1007/s12185-014-1636-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v97.1.101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041990794"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.13954", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048959933"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.12.052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051404441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/clm.2009.n.044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052722682"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2016.67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053311210", 
          "https://doi.org/10.1038/bmt.2016.67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v99.12.4336", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053511143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.11.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.11.076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.08.043", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/1389201013378545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069176688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.12.3793", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074556143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074999752", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075247799", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018", 
    "datePublishedReg": "2018-01-01", 
    "description": "Ibritumomab tiuxetan labeled with yttrium-90 (90Y) is one of the excellent therapeutic options for patients with low-grade B cell non-Hodgkin lymphoma (NHL) who have relapsed disease after first-line chemotherapy regimens and are reluctant to the precedent therapy. The overall response rate (ORR) of 80\u201390% and the complete response rate (CR) of 30\u201369% have been reported for patients with relapsed or refractory low-grade B cell NHL. It has also an established role as a consolidation therapy agent after first-line chemotherapy. Ibritumomab tiuxetan has also proved to be an efficient and feasible treatment option as first-line therapy. The short-term toxicity associated with ibritumomab tiuxetan is mainly reversible bone marrow suppression. For diffuse large B cell lymphoma, which is the most frequent NHL subtype, ibritumomab tiuxetan has been also introduced as conditioning therapy added to conventional conditioning regimens before stem cell transplantation.", 
    "editor": [
      {
        "familyName": "Hosono", 
        "givenName": "Makoto", 
        "type": "Person"
      }, 
      {
        "familyName": "Chatal", 
        "givenName": "Jean-Fran\u00e7ois", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-78238-6_1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-78237-9", 
        "978-3-319-78238-6"
      ], 
      "name": "Resistance to Ibritumomab in Lymphoma", 
      "type": "Book"
    }, 
    "name": "Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma", 
    "pagination": "1-8", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-78238-6_1"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d2cfb915b0b3110d1b2a1cb1c8dc6de8a09b416ebc0b4fbaae337f83ed510729"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1103656348"
        ]
      }
    ], 
    "publisher": {
      "location": "Cham", 
      "name": "Springer International Publishing", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-78238-6_1", 
      "https://app.dimensions.ai/details/publication/pub.1103656348"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2019-04-15T12:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000604.jsonl", 
    "type": "Chapter", 
    "url": "http://link.springer.com/10.1007/978-3-319-78238-6_1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-78238-6_1'


 

This table displays all metadata directly associated to this object as RDF triples.

183 TRIPLES      23 PREDICATES      61 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-78238-6_1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N8e4f3c5b25bc49018fa807cc51c27c3c
4 schema:citation sg:pub.10.1007/s12185-014-1636-5
5 sg:pub.10.1038/bmt.2016.67
6 https://app.dimensions.ai/details/publication/pub.1074999752
7 https://app.dimensions.ai/details/publication/pub.1075247799
8 https://doi.org/10.1002/cncr.22066
9 https://doi.org/10.1002/cncr.22617
10 https://doi.org/10.1016/j.clml.2011.03.007
11 https://doi.org/10.1016/j.critrevonc.2016.07.008
12 https://doi.org/10.1053/j.seminoncol.2003.10.007
13 https://doi.org/10.1093/annonc/mdr145
14 https://doi.org/10.1111/bjh.13954
15 https://doi.org/10.1111/j.1349-7006.2005.00120.x
16 https://doi.org/10.1111/j.1349-7006.2008.00999.x
17 https://doi.org/10.1158/1078-0432.ccr-08-0529
18 https://doi.org/10.1182/blood-2004-08-3175
19 https://doi.org/10.1182/blood-2005-01-0016
20 https://doi.org/10.1182/blood-2007-01-068056
21 https://doi.org/10.1182/blood.v97.1.101
22 https://doi.org/10.1182/blood.v99.12.4336
23 https://doi.org/10.1200/jco.1999.17.12.3793
24 https://doi.org/10.1200/jco.2002.11.017
25 https://doi.org/10.1200/jco.2002.11.076
26 https://doi.org/10.1200/jco.2003.08.043
27 https://doi.org/10.1200/jco.2005.12.052
28 https://doi.org/10.1200/jco.2006.09.2882
29 https://doi.org/10.1200/jco.2008.17.2015
30 https://doi.org/10.1200/jco.2011.41.1553
31 https://doi.org/10.1200/jco.2012.45.6400
32 https://doi.org/10.1200/jco.2013.50.3110
33 https://doi.org/10.18632/oncotarget.6531
34 https://doi.org/10.2174/1389201013378545
35 https://doi.org/10.3109/10428194.2011.635857
36 https://doi.org/10.3324/haematol.2013.093450
37 https://doi.org/10.3816/clm.2009.n.044
38 schema:datePublished 2018
39 schema:datePublishedReg 2018-01-01
40 schema:description Ibritumomab tiuxetan labeled with yttrium-90 (90Y) is one of the excellent therapeutic options for patients with low-grade B cell non-Hodgkin lymphoma (NHL) who have relapsed disease after first-line chemotherapy regimens and are reluctant to the precedent therapy. The overall response rate (ORR) of 80–90% and the complete response rate (CR) of 30–69% have been reported for patients with relapsed or refractory low-grade B cell NHL. It has also an established role as a consolidation therapy agent after first-line chemotherapy. Ibritumomab tiuxetan has also proved to be an efficient and feasible treatment option as first-line therapy. The short-term toxicity associated with ibritumomab tiuxetan is mainly reversible bone marrow suppression. For diffuse large B cell lymphoma, which is the most frequent NHL subtype, ibritumomab tiuxetan has been also introduced as conditioning therapy added to conventional conditioning regimens before stem cell transplantation.
41 schema:editor N5d51d5a819ae4cb9bcdc1f8ccc9d055d
42 schema:genre chapter
43 schema:inLanguage en
44 schema:isAccessibleForFree false
45 schema:isPartOf N82048145d8d94ba2b90eca22d3e83813
46 schema:name Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma
47 schema:pagination 1-8
48 schema:productId N32b57ee3180e4d2e95060c785eff6be4
49 N586e1eb1bb564edf9ea3e0c77ca48268
50 N5907dc23e98242bb93145edc34d9a830
51 schema:publisher Nf61b00cd4dff428eb881e0028de82b25
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103656348
53 https://doi.org/10.1007/978-3-319-78238-6_1
54 schema:sdDatePublished 2019-04-15T12:13
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher Nb1942e3d73304e78b8103f2d44fe4135
57 schema:url http://link.springer.com/10.1007/978-3-319-78238-6_1
58 sgo:license sg:explorer/license/
59 sgo:sdDataset chapters
60 rdf:type schema:Chapter
61 N1393af8f016947e39d636f4bb0fd5feb schema:familyName Chatal
62 schema:givenName Jean-François
63 rdf:type schema:Person
64 N32b57ee3180e4d2e95060c785eff6be4 schema:name readcube_id
65 schema:value d2cfb915b0b3110d1b2a1cb1c8dc6de8a09b416ebc0b4fbaae337f83ed510729
66 rdf:type schema:PropertyValue
67 N586e1eb1bb564edf9ea3e0c77ca48268 schema:name doi
68 schema:value 10.1007/978-3-319-78238-6_1
69 rdf:type schema:PropertyValue
70 N5907dc23e98242bb93145edc34d9a830 schema:name dimensions_id
71 schema:value pub.1103656348
72 rdf:type schema:PropertyValue
73 N5d51d5a819ae4cb9bcdc1f8ccc9d055d rdf:first Ndaf75e57f78a4023b50279e310f72e61
74 rdf:rest Nd878a004d7584d4aa193c4593395f314
75 N82048145d8d94ba2b90eca22d3e83813 schema:isbn 978-3-319-78237-9
76 978-3-319-78238-6
77 schema:name Resistance to Ibritumomab in Lymphoma
78 rdf:type schema:Book
79 N8e4f3c5b25bc49018fa807cc51c27c3c rdf:first sg:person.0745256126.40
80 rdf:rest N9038326ba3d044e79cec0114c79c692f
81 N9038326ba3d044e79cec0114c79c692f rdf:first sg:person.01002213667.77
82 rdf:rest rdf:nil
83 Nb1942e3d73304e78b8103f2d44fe4135 schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 Nd878a004d7584d4aa193c4593395f314 rdf:first N1393af8f016947e39d636f4bb0fd5feb
86 rdf:rest rdf:nil
87 Ndaf75e57f78a4023b50279e310f72e61 schema:familyName Hosono
88 schema:givenName Makoto
89 rdf:type schema:Person
90 Nf61b00cd4dff428eb881e0028de82b25 schema:location Cham
91 schema:name Springer International Publishing
92 rdf:type schema:Organisation
93 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
94 schema:name Medical and Health Sciences
95 rdf:type schema:DefinedTerm
96 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
97 schema:name Oncology and Carcinogenesis
98 rdf:type schema:DefinedTerm
99 sg:person.01002213667.77 schema:affiliation https://www.grid.ac/institutes/grid.416533.6
100 schema:familyName Uike
101 schema:givenName Naokuni
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002213667.77
103 rdf:type schema:Person
104 sg:person.0745256126.40 schema:affiliation https://www.grid.ac/institutes/grid.470350.5
105 schema:familyName Choi
106 schema:givenName Ilseung
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745256126.40
108 rdf:type schema:Person
109 sg:pub.10.1007/s12185-014-1636-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039937702
110 https://doi.org/10.1007/s12185-014-1636-5
111 rdf:type schema:CreativeWork
112 sg:pub.10.1038/bmt.2016.67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053311210
113 https://doi.org/10.1038/bmt.2016.67
114 rdf:type schema:CreativeWork
115 https://app.dimensions.ai/details/publication/pub.1074999752 schema:CreativeWork
116 https://app.dimensions.ai/details/publication/pub.1075247799 schema:CreativeWork
117 https://doi.org/10.1002/cncr.22066 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036856009
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1002/cncr.22617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012922266
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/j.clml.2011.03.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010638416
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/j.critrevonc.2016.07.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022344315
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1053/j.seminoncol.2003.10.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034380348
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1093/annonc/mdr145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019581117
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1111/bjh.13954 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048959933
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1111/j.1349-7006.2005.00120.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023063407
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1111/j.1349-7006.2008.00999.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001118083
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1158/1078-0432.ccr-08-0529 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018226479
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1182/blood-2004-08-3175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033024465
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1182/blood-2005-01-0016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019752393
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1182/blood-2007-01-068056 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025973696
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1182/blood.v97.1.101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041990794
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1182/blood.v99.12.4336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053511143
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1200/jco.1999.17.12.3793 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074556143
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1200/jco.2002.11.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203164
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1200/jco.2002.11.076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203176
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1200/jco.2003.08.043 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203782
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1200/jco.2005.12.052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051404441
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1200/jco.2006.09.2882 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022216179
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1200/jco.2008.17.2015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022228089
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1200/jco.2011.41.1553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019738515
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1200/jco.2012.45.6400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027703974
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1200/jco.2013.50.3110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021633071
166 rdf:type schema:CreativeWork
167 https://doi.org/10.18632/oncotarget.6531 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035060800
168 rdf:type schema:CreativeWork
169 https://doi.org/10.2174/1389201013378545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069176688
170 rdf:type schema:CreativeWork
171 https://doi.org/10.3109/10428194.2011.635857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022329553
172 rdf:type schema:CreativeWork
173 https://doi.org/10.3324/haematol.2013.093450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026609111
174 rdf:type schema:CreativeWork
175 https://doi.org/10.3816/clm.2009.n.044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052722682
176 rdf:type schema:CreativeWork
177 https://www.grid.ac/institutes/grid.416533.6 schema:alternateName Saga-Ken Medical Centre Koseikan
178 schema:name Saga-ken Medical Centre Koseikan
179 rdf:type schema:Organization
180 https://www.grid.ac/institutes/grid.470350.5 schema:alternateName National Hospital Organization Kyushu Cancer Center
181 schema:name National Hospital Organization Kyushu Cancer Center
182 National Kyushu Cancer Center
183 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...